Саркопения и неалкогольная жировая болезнь печени - сложные патогенетические взаимосвязи
https://doi.org/10.31146/1682-8658-ecg-229-9-110-118
Аннотация
Саркопения и неалкогольная жировая болезнь печени (НАЖБП) являются частыми проблемами, ассоциированными со старением. Несмотря на различия в методах диагностики, в последние годы появилась серия исследований в которых была выявлена тесная связь между саркопенией и НАЖБП. Саркопения и НАЖБП связаны целым рядом общих патогенетических механизмов, которые рассмотрены в представленной статье, включая роль резистентности к инсулину как на уровне печени, так и на уровне мышц, гормональный дисбаланс, роль системного воспаления, нарушения регуляции миокинов, дефицит витамина Д, роль неправильного питания и гиподинамии, роли гепатокинов и гипераммониемии, что указывает на двунаправленную взаимосвязь между саркопенией и НАЖБП.
Ключевые слова
Об авторах
В. А. Ахмедов
Федеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Россия
Россия
В. С. Мариненко
Федеральное государственное бюджетное образовательное учреждение высшего образования «Майкопский государственный технологический университет»
Россия
Россия
Список литературы
1. Cruz-Jentoft AJ., Bahat G., Bauer J. et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019; 48: 601. doi: 10.1093/ageing/afz046.
2. Rosenberg, IH. Sarcopenia: Origins and clinical relevance. J. Nutr. 1997; 127: 990S-991S. doi: 10.1093/jn/127.5.990S.
3. Cruz-Jentoft AJ., Baeyens J.P., Bauer J.M. et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39: 412-423. doi: 10.1093/ageing/afq034.
4. Shafiee G., Keshtkar A., Soltani A. et al. Prevalence of sarcopenia in the world: A systematic review and meta- analysis of general population studies. J. Diabetes Metab. Disord. 2017; 16: 21. doi: 10.1186/s40200-017-0302-x.
5. Roh E., Hwang S.Y., Yoo H.J. et al. Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study. Hepatol Int. 2022;16(3):545-554. doi: 10.1007/s12072-021-10258-8.
6. Zambon Azevedo V., Silaghi C.A., Maurel T. et al. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. Front Nutr. 2022;8:774030. doi: 10.3389/fnut.2021.774030.
7. Lee HJ., Lee D.C., Kim C.O. Association Between 10-Year Fracture Probability and Nonalcoholic Fatty Liver Disease With or Without Sarcopenia in Korean Men: A Nationwide Population-Based Cross-Sectional Study. Front Endocrinol (Lausanne). 2021;12:599339. doi: 10.3389/fendo.2021.599339.
8. Moon J.H., Koo B.K., Kim W. Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey. J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):964-972. doi: 10.1002/jcsm.12719.
9. Charatcharoenwitthaya P., Karaketklang K., Aekplakorn W. Muscle strength, but not body mass index, is associated with mortality in patients with non-alcoholic fatty liver disease. J Cachexia Sarcopenia Muscle. 2022;13(5):2393-2404. doi: 10.1002/jcsm.13001.
10. Kuchay M.S., Martínez-Montoro J.I., Kaur P. et al.Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: An altered liver-muscle crosstalk leading to increased mortality risk. Ageing Res Rev. 2022;80:101696. doi: 10.1016/j.arr.2022.101696.
11. Joo SK., Kim W.Interaction between sarcopenia and nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl): S68-S78. doi: 10.3350/cmh.2022.0358.
12. Iwaki M., Kobayashi T., Nogami A. et al. Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease. Nutrients. 2023;15(4):891. doi: 10.3390/nu15040891.
13. Kawaguchi T., Takahashi H., Gerber L.H. Clinics in Liver Disease: Update on Nonalcoholic Steatohepatitis: Sarcopenia and Nonalcoholic Fatty Liver Disease. Clin Liver Dis. 2023;27(2):275-286. doi: 10.1016/j.cld.2023.01.005.
14. Sung MJ., Lim TS., Jeon MY. et al. Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. Gut Liver. 2020;14(5):626-635. doi: 10.5009/gnl19126.
15. El Sherif O., Dhaliwal A., Newsome P.N. et al. Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice. Expert Rev Gastroenterol Hepatol. 2020;14(3):197-205. doi: 10.1080/17474124.2020.1731303.
16. Chung GE., Kim MJ., Yim JY. et al. Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease. J Obes Metab Syndr. 2019;28(2):129-138. doi: 10.7570/jomes.2019.28.2.129.
17. Lee I., Kim J., Kang H. Estimated Cardiorespiratory Fitness Attenuates the Impacts of Sarcopenia and Obesity on Non-Alcoholic Fatty Liver in Korean Adults.Int J Environ Res Public Health. 2020;17(11):3902. doi: 10.3390/ijerph17113902.
18. Lee YH., Kim SU.Sarcopenia: an emerging risk factor for non-alcoholic fatty liver disease. Hepatol Int. 2020;14(1):5-7. doi: 10.1007/s12072-019-09999-4.
19. Hittel DS., Berggren JR., Shearer J. et al. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes. 2009;58:30-8. doi: 10.2337/db08-0943
20. Kim H.K., Bae S.J., Lee M.J. et al. Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity. J. Clin Mol Hepatol. 2023;29(4):987-1001. doi: 10.3350/cmh.2023.0035.
21. Chung G.E., Oh S., Ahn D.W. et al. Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease. Sci Rep. 2023;13(1):3628. doi: 10.1038/s41598-023-30833-3.
22. Chung H.H. Enhanced muscle function in cause-specific mortality among patients with NAFLD-related sarcopenia. Liver Int. 2023;43(8):1837-1838. doi: 10.1111/liv.15617.
23. Cahill G.F., Herrera M.G., Morgan A.P. et al. Hormone-fuel interrelationships during fasting. J Clin Invest. 1966; 45:1751-69. doi: 10.1172/JCI105481
24. Goodpaster BH., Sparks LM. Metabolic flexibility in health and disease. Cell Metab. 2017; 25:1027-36. doi: 10.1016/j.cmet.2017.04.015
25. Polyzos S.A., Vachliotis I.D., Mantzoros C.S. Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease. Metabolism. 2023;147:155676. doi: 10.1016/j.metabol.2023.155676.
26. Bali T., Chrysavgis L., Cholongitas E. Metabolic-Associated Fatty Liver Disease and Sarcopenia. Endocrinol Metab Clin North Am. 2023;52(3):497-508. doi: 10.1016/j.ecl.2023.02.004.
27. Nachit M., Lanthier N., Rodriguez J. et al. A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients. JHEP Rep. 2021;3(4):100323. doi: 10.1016/j.jhepr.2021.100323.
28. Kouvari M., Polyzos SA., Chrysohoou C. et al. Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study. Clin Nutr. 2022;41(6):1281-1289. doi: 10.1016/j.clnu.2022.03.022.
29. Seo J.Y., Cho E.J., Kim M.J. et al. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. J Cachexia Sarcopenia Muscle. 2022;13(6):2953-2960. doi: 10.1002/jcsm.13099.
30. Shirakami Y., Kato J., Maeda T. et al. Skeletal muscle atrophy is exacerbated by steatotic and fibrotic liver-derived TNF-α in senescence-accelerated mice. J Gastroenterol Hepatol. 2023;38(5):800-808. doi: 10.1111/jgh.16171.
31. Kob R., Bollheimer LC., Bertsch T. et al. Sarcopenic obesity: molecular clues to a better understanding of its pathogenesis? Biogerontology. 2015;16:15-29. doi: 10.1007/s10522-014-9539-7.
32. Kim TH., Jeong CW., Lee C. et al. Association between Body Composition Contents and Hepatic Fibrosis in Sarcopenic Obesity. J Clin Med. 2023;12(13):4279. doi: 10.3390/jcm12134279.
33. Obstfeld AE., Sugaru E., Thearle M. et al. Chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes. 2010;59:916-25. doi: 10.2337/db09-1403.
34. Zhao Q., Yin Y., Deng Y. Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study. Nutr Diabetes. 2023;13(1):21. doi: 10.1038/s41387-023-00250-6.
35. Yan F., Nie G., Zhou N. et al. Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study. BMJ Open. 2023;13(10): e072489. doi: 10.1136/bmjopen-2023-072489.
36. Lee JH., Lee HS., Lee BK. et al. Relationship between Muscle Mass and Non-Alcoholic Fatty Liver Disease. Biology (Basel). 2021;10(2):122. doi: 10.3390/biology10020122.
37. Wu H.T. Ou H-Y. Hung H-C. et al. Novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes. Diabetologia. 2016; 59:1732-1742. doi: 10.1007/s00125-016-3991-7.
38. Jung TW., Chung YH., Kim H-C. et al. Hyperlipidemia-induced hepassocin in the liver contributes to insulin resistance in skeletal muscle. Mol Cell Endocrinol. 2018;470:26-33. doi: 10.1016/j.mce.2017.10.014.
39. Mukhopadhyay S., Bhattacharya S. Plasma fetuin-A triggers inflammatory changes in macrophages and adipocytes by acting as an adaptor protein between NEFA and TLR-4. Diabetologia. 2016; 59:859-860. doi: 10.1007/s00125-016-3866-y.
40. Camporez J.P.G., Jornayvaz F.R., Petersen M.C. et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology. 2013;154:3099-109. doi: 10.1210/en.2013-1191.
41. Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017; 13:509-520. doi: 10.1038/nrendo.2017.56.
42. Kim S.H., Jeong J.B., Kang J. et al. Association between sarcopenia level and metabolic syndrome. PLoS One. 2021;16(3): e0248856. doi: 10.1371/journal.pone.0248856.
43. Yang Q., Graham TE., Mody N. et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356-362. doi: 10.1038/nature03711.
44. Han E., Kim M.K., Im S.S. et al. Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity. J Diabetes Complications. 2022;36(8):108253. doi: 10.1016/j.jdiacomp.2022.108253.
45. Cho Y., Park H.S., Huh B.W. et al. Non-Alcoholic Fatty Liver Disease with Sarcopenia and Carotid Plaque Progression Risk in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2023;47(2):232-241. doi: 10.4093/dmj.2021.0355.
46. Dijk W., Beigneux A.P., Larsson M. et al. Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes. J Lipid Res. 2016; 57:1670-1683. doi: 10.1194/jlr.M067363.
47. Thomsen K.L., Eriksen P.L., Kerbert A.J. et al. Role of ammonia in NAFLD: An unusual suspect. JHEP Rep. 2023;5(7):100780. doi: 10.1016/j.jhepr.2023.100780.
48. Musio A., Perazza F., Leoni L. et al.Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease.Int J Mol Sci. 2023;24(8):7517. doi: 10.3390/ijms24087517.
49. Chen M., Cao Y., Ji G. et al. Lean nonalcoholic fatty liver disease and sarcopenia. Front Endocrinol (Lausanne). 2023;14:1217249. doi: 0.3389/fendo.2023.1217249.
50. Tajiri K., Shimizu Y. Branched-chain amino acids in liver diseases. Transl. Gastroenterol. Hepatol. 2018; 3: 47. doi: 10.21037/tgh.2018.07.06.
51. Davuluri G., Allawy A., Thapaliya S. et al. Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress. J. Physiol. 2016; 594: 7341-7360. doi: 10.1113/JP272796.
52. Yang Y.J., Kim D.J. An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia.Int J Mol Sci. 2021;22(5):2604. doi: 10.3390/ijms22052604.
53. Pang Q. Qu K. Liu C. et al. Sarcopenia and nonalcoholic fatty liver disease: New evidence for low vitamin D status contributing to the link. Hepatol Baltim Md. 2016;63:675. doi: 10.1002/hep.28010.
54. Muir S.W., Montero-Odasso M. Effect of vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2011; 59:2291-300. doi: 10.1111/j.1532-5415.2011.03733.x.
55. Stockton K.A., Mengersen K., Paratz J.D. et al. Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2011; 22:859-71. doi: 10.1007/s00198-010-1407-y.
56. Eliades M., Spyrou E., Agrawal N. Metaanalysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013; 38:246-254. doi: 10.1111/apt.12377.
57. Lai R., Nguyen M.H. Risk Stratification for Sarcopenic Obesity in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2023;21(11):2984. doi: 10.1016/j.cgh.2023.02.012.
58. Cabrera D., Ruiz A., Cabello-Verrugio C. et al. Diet-induced nonalcoholic fatty liver disease is associated with sarcopenia and decreased serum insulin-like growth factor-1. Dig Dis Sci. 2016; 61:3190-8. doi: 10.1007/s10620-016-4285.
59. Nachit M., De Rudder M., Thissen J-P. et al. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models. J Cachexia Sarcopenia Muscle. 2021; 12:144-158. doi: 10.1002/jcsm.12646.
60. Poggiogalle E., Lubrano C., Gnessi L. et al. Fatty liver index associates with relative sarcopenia and GH/IGF-1 status in obese subjects. PLoS ONE. 2016; 11: e0145811. doi: 10.1371/journal.pone.0145811.
61. Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. Br J Pharmacol. 2008; 154:522-8. doi: 10.1038/bjp.2008.118.
62. Nettleship J.E., Pugh P.J., Channer K.S. et al. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2007; 39:366-71. doi: 10.1055/s-2007-976543.
63. Kalyani R.R., Corriere M., Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014; 2:819-29. doi: 10.1016/S2213-8587(14)70034-8.
64. Abdulnour J., Doucet E., Brochu M. et al. The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa New Emerging Team group study. Menopause N Y N. 2012; 19:760-767. doi: 10.1097/gme.0b013e318240f6f3.
65. Kim D., Dennis BB., Wijarnpreecha K. et al. Muscle strength in non-alcoholic fatty liver disease and all-cause and cause-specific mortality. Liver Int. 2023;43(2):513-516. doi: 10.1111/liv.15498.
66. Chun H.S., Lee M., Lee H, A. et al. Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2023;21(2):358-369.e12. doi: 10.1016/j.cgh.2021.12.043.
67. Yamamoto S., Honma K., Fujii M. et al. al. SHRSP5/Dmcr rats fed a high-fat and high-cholesterol diet develop disease-induced sarcopenia as nonalcoholic steatohepatitis progresses. Ann Anat. 2023;249:152104. doi: 10.1016/j.aanat.2023.152104.
68. Lecoultre V., Egli L., Carrel G. et al. Effects of fructose and glucose overfeeding on hepatic insulin sensitivity and intrahepatic lipids in healthy humans. Obes Silver Spring Md. 2013; 21:782-785. doi: 10.1002/oby.20377.
69. El Sherif O., Dhaliwal A., Newsome P.N. et al. Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice. Expert Rev Gastroenterol Hepatol. 2020;14(3):197-205. doi: 10.1080/17474124.2020.1731303.
70. Chun H.S., Lee M., Lee H.A. et al. Risk Stratification for Sarcopenic Obesity in Subjects With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2023;21(9):2298-2307.e18. doi: 10.1016/j.cgh.2022.11.031.
71. Gonzalez A., Valero-Breton M., Huerta-Salgado C. et al. Cabello-Verrugio C. Impact of exercise training on the sarcopenia criteria in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Transl Myol. 2021; 31:9630. doi: 10.4081/ejtm.2021.9630.
72. Han E., Kim M.K., Im S.S. et al. High Sodium Intake, as Assessed by Urinary Sodium Excretion, Is Associated with Nonalcoholic Fatty Liver Disease or Sarcopenia. Gut Liver. 2023;17(3):456-465. doi: 10.5009/gnl220133.
73. Ha N.B., Lai J.C. The bidirectional relationship between nonalcoholic fatty liver disease and sarcopenia. Hepatol Int. 2022;16(3):489-491. doi: 10.1007/s12072-022-10333-8.
74. Elkina Y., von Haehling S. Anker S.D. et al. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011; 2:143-151. doi: 10.1007/s13539-011-0035-5.
75. DeloguW., Caligiuri A., Provenzano A. et al. Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via cjun N-terminal kinase activation. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2019; 51:1400-1408. doi: 10.1016/j.dld.2019.03.002.
76. Huh J.Y., Dincer F., Mesfum E. et al. Irisin stimulates muscle growthrelated genes and regulates adipocyte differentiation and metabolism in humans.Int J Obes. 2014; 38:1538-44. doi: 10.1038/ijo.2014.42.
77. Seldin M.M., Peterson J.M., Byerly M.S. et al. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012; 287:11968-11980. doi: 10.1074/jbc.M111.336834.
Рецензия
Для цитирования:
Ахмедов В.А., Мариненко В.С. Саркопения и неалкогольная жировая болезнь печени - сложные патогенетические взаимосвязи. Экспериментальная и клиническая гастроэнтерология. 2024;(9):110-118. https://doi.org/10.31146/1682-8658-ecg-229-9-110-118
For citation:
Akhmedov V.A., Marinenko V.S. Sarcopenia and non-alcoholic fatty liver disease - complex pathogenetic relationships. Experimental and Clinical Gastroenterology. 2024;(9):110-118. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-229-9-110-118
Просмотров:
163
Послать статью по эл. почте 